Hemoglobin E (HbE) is a form of hemoglobin resulting from a mutation in the HBB gene located on chromosome 11. Hemoglobin E-associated disease is often considered a beta-thalassemia, which involves substitution of amino acids in the globin chains. As a result, the structural and functional form of hemoglobin is altered, which can lead to various hemoglobinopathies, including anemia, enlarged spleen, and other associated conditions. In particular, patients with hemoglobin E may have elements of susceptibility to more serious blood disorders due to impaired oxygen transport and an increased tendency to hemolysis. Proper diagnosis and early intervention are key in the management of hemoglobin E-associated diseases, as they can range from mild to severe.
History of the disease and interesting historical facts
The history of hemoglobin E begins in Southeast Asia, where the mutation was first reported. In Thailand and other countries in the region, HbE is found at frequencies up to 30% in some ethnic groups. The scientific community began studying hemoglobin E in the 1950s, when the first genetic sequence was conducted. This study initiated attention to the problems associated with hemoglobinopathies in general. Of particular interest is that HbE has long been considered a “protective” variant due to its association with reduced susceptibility to tropical infections, which is supported by several studies.
Epidemiology
According to epidemiological studies, hemoglobin E is common in some regions with high frequency. For example, among the population of certain communities in Thailand, Cambodia, Laos and Myanmar, the carrier rate can reach 30%. In other countries, including India, it is also found, but with a lower frequency. According to studies, hemoglobin E can be combined with other mutations, such as beta-thalassemia and hemoglobin C, which aggravates the clinical picture. This makes the study of the disease important for healthcare in these regions, since its consequences can have a significant impact on the quality of life and overall health of the population.
Genetic predisposition to this disease
Genetic aspects of hemoglobin E are an important part of understanding the disease. Hemoglobin E results from a mutation in the β-globin chain caused by a substitution of adenine for cytosine at codon 26 of the HBB gene. This mutation results in maladapted hemoglobin and, consequently, disruption of normal red blood cell function. The role of polygenic factors is also important, as susceptibility to hemoglobin E may coexist with other mutations, such as those that cause beta-thalassemia. Multiple mutations in HBB may determine the severity of the disease.
Risk factors for the development of this disease
Despite the genetic predisposition, a number of risk factors can be identified that contribute to the development of the disease:
- Heredity. The presence of hemoglobin E carriers in the family increases the likelihood of its occurrence in children.
- Ethnicity: People from areas with a high prevalence of hemoglobin E are at greater risk.
- Living conditions and ecology. Low levels of medical care in areas with high prevalence of the disease can contribute to its severe forms.
Diagnosis of this disease
Diagnosis of hemoglobin E is based on clinical signs and laboratory tests. The main symptoms may include:
- Anemia, which is expressed in increased fatigue and pallor.
- Enlargement of the spleen or liver.
- Symptoms similar to acute anemia, such as dizziness and increased heart rate.
Laboratory tests aimed at diagnosis may include hemoglobin and its fractions, red blood cells, and hemolysis markers. Radiological tests, such as abdominal ultrasound, may help identify enlarged organs. Differential diagnosis is important to exclude other conditions, such as beta-thalassemia or sickle cell anemia.
Treatment
Treatment for hemoglobin E varies depending on the severity of the condition. The focus is on controlling symptoms and preventing complications. General treatment may include:
- Supportive therapy, such as iron supplements.
- Pharmacological treatment using erythropoietin to manage anemia.
- In severe cases, a bone marrow transplant may be required.
List of medications used to treat this disease
Among the medications used to treat hemoglobin E, the following can be distinguished:
- Ferrum Lek - to maintain iron levels.
- Erythropoietin alpha - to stimulate erythropoiesis.
- Hydroxyurea - to improve the condition of blood cells.
Disease monitoring
Patient monitoring includes monitoring hemoglobin levels, organ function, and possible complications. Prognosis can range from good in mild cases to serious in severe cases. Complications may include sickle cell disease, iron hyperdysregulation, and infections.
Age-related features of the disease
The hemoglobin E form may manifest itself differently depending on age. In newborns, the disease may proceed without symptoms, but with age, symptoms of anemia and an enlarged spleen may develop. In children and adolescents, the likelihood of abnormal growth is also high, which requires special attention in the context of monitoring and possible treatment. In the elderly, severe forms of the disease with a large number of concomitant pathologies may manifest.
Questions and Answers
- What is hemoglobin E? - It is a change in hemoglobin caused by a mutation in the HBB gene, which leads to blood diseases.
- How is hemoglobin E diagnosed? - Through laboratory tests, determination of hemoglobin levels and clinical observation of symptoms.
- How is the disease treated? — Treatment ranges from supportive care to complex methods such as bone marrow transplantation in severe cases.
- Does hemoglobin E only appear in certain ethnic groups? - Yes, it is more common among certain peoples of Southeast Asia.
- What complications can arise from the disease? — Iron hyperdysregulation, infections and severe forms of anemia.
Advice from Dr. Oleg Korzhikov
If you or someone you know is a carrier of hemoglobin E, it is important to pay special attention to regular check-ups. Don’t forget about a diet rich in vitamins and minerals to support your body. Discuss with your doctor the need to monitor your hemoglobin levels and other blood parameters. It is also important to monitor changes in your health and contact a specialist if new symptoms appear. Prevention and early diagnosis can significantly improve the quality of life with this disease.
